Duchenne muscular dystrophy (DMD) is a monogenic disorder and a candidate for therapeutic genome editing. There have been several recent reports of genome editing in preclinical models of Duchenne muscular dystrophy 1-6 , however, the long-term persistence and safety of these genome editing approaches have not been addressed. Here we show that genome editing and dystrophin protein restoration is sustained in the mdx mouse model of Duchenne muscular dystrophy for 1 year after a single intravenous administration of an adeno-associated virus that encodes CRISPR (AAV-CRISPR). We also show that AAV-CRISPR is immunogenic when administered to adult mice 7 ; however, humoral and cellular immune responses can be avoided by treating neonatal mice. Additionally, we describe unintended genome and transcript alterations induced by AAV-CRISPR that should be considered for the development of AAV-CRISPR as a therapeutic approach. This study shows the potential of AAV-CRISPR for permanent genome corrections and highlights aspects of host response and alternative genome editing outcomes that require further study.
RNAs (gRNAs) that were designed to excise exon 23 from the Dmd gene in mdx mice. For viral packaging, we used the smaller 3.2-kb Cas9 derived from Staphylococcus aureus (SaCas9) 17 . We examined both AAV serotype 8 (AAV8) and 9 (AAV9) ( Fig. 1a,b ), which have differential tissue tropism for the heart, skeletal muscle, and liver in animal models that are not perfectly predictive of human tropism 18 . We examined adult and postnatal day 2 (P2) neonatal mice treated locally by intramuscular (i.m.) injection and systemically by intravenous facial-vein injection (FVI), respectively, for restoration of dystrophin expression ( Fig. 1a,b ). We adapted an unbiased deep-sequencing method for precise quantification of gene-editing efficiencies. Mice injected by i.m. injection as adults had a significant decrease in genome-editing levels over time ( Fig. 1c and Extended Data Fig. 1 ). By contrast, systemically treated mice had a modest statistically significant increase in genomeediting levels over 1 year ( Fig. 1d and Extended Data Fig. 1 ). The SaCas9 expression cassette was driven by a constitutive CMV promoter that is expressed in multiple muscle cell types, including striated muscle and muscle progenitors 5 . However, genomeediting events were also detected in other tissues, including liver, spleen, kidney and brain, as well as the testis at levels barely above the limit of detection (approximately 0.1%; Extended Data Fig. 2 ). Use of a myocyte-specific promoter could restrict editing to striated muscle nuclei 6 , but potentially at the cost of editing muscle progenitor cells. Analysis of Dmd mRNA transcripts by droplet digital PCR (ddPCR) showed the same trend as the genomic deletions with significant increases over time noted in cardiac muscles obtained from systemically treated mice ( Fig. 1e,f ). Sustained restoration of dystrophin was detected by immunofluorescence staining and western blot of cardiac and skeletal muscle from systemically treated mice for at least 1 year after a single administration (Fig. 1g,h and Extended Data Fig. 3 ). The restored dystrophin was slightly smaller in younger mice than in older mice, potentially owing to a smaller protein isoform produced at the early time point while nearly full-length dystrophin was detected at 1 year. Serum creatine kinase levels were reduced at 8 weeks after treatment in mice treated systemically as neonates, demonstrating protection from muscle damage by the restored dystrophin protein (Fig. 1i ). Deep sequencing of the top ten predicted off-target sites showed no significant increase in off-target cutting after 1 year with slight activity above background noted for gRNA1 at offtarget site 8 (gRNA1-OT8), as was previously identified following local administration 4 (Supplementary Tables 1 and 2 ).
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An important consideration to long-term therapeutic benefit of in vivo genome editing is the host response to bacteria-derived Cas9 proteins. In our study, a humoral immune response was detected against the SaCas9 protein in nearly all mice injected as adults (n = 31 out of 32 mice; Fig. 2a and Extended Data Fig. 4 ). By contrast, no humoral response against SaCas9 was detected in mice treated as neonates by FVI or intraperitoneal injections (n = 0 out of 19 mice; Fig. 2a ). A cellular response was detected by restimulation with SaCas9 to produce interferon (IFN)γ-secreting T cells in mice treated as adults but not neonates, regardless of administration route ( Fig. 2b and Extended Data Fig. 4) . The mdx mouse model has an increased baseline number of infiltrating macrophages and neutrophils owing to muscle degeneration and inflammation 19 , which treatment with AAV-CRISPR has been shown to decrease 4 . Expression of FOXP3, granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-1β, and IL-12β decreased relative to untreated mdx mice after i.m. injection. However, IFNγ significantly increased approximately seven-fold after local injection relative to untreated mdx mice (Extended Data Fig. 4 ). By contrast, systemically treated adults and neonates showed no significant changes in these markers of inflammatory cell infiltration. Most AAV vector genomes remain episomal after cell entry and are stably maintained in non-dividing cells 20 . In this study, AAV vectors persisted between 8 weeks and 1 year in cardiac muscle but were significantly lost in skeletal muscle after i.m. or FVI injection ( Fig. 2c,d) .
Regardless, expression of SaCas9 mRNA and both gRNAs is almost absent after 6 months or 1 year by either route of administration ( Fig. 2e ,f), which may be the result of promoter silencing 21 . The host response to AAV-CRISPR will need to be carefully considered for future clinical development, including pre-existing immunity in humans 22 . We have previously shown CRISPR-based gene silencing elicits a Cas9-dependent host response that resolves without intervention in vivo 23 . Our data here indicates that a significant host response is avoided if AAV-CRISPR is administered at the neonatal stage. Although the P2 mice have an undeveloped immune system that can be exploited for antigen-specific tolerance including Cas9 24-26 , it is not yet clear to what extent this approach applies in newborn humans. Other methods that could be explored to avoid anti-Cas9 immune response include transient immunosuppression for the length of vector expression, induction of immune tolerance 27 , removal of T cell epitopes 28 , the use of self-limiting/cleaving vectors, or other transient delivery vehicles including non-viral vectors 29 .
The methods used to assess in vivo genome-editing efficiencies have typically been designed to quantify the frequency of expected genome-editing outcomes. Additionally, different methods often must be used to quantify the various possible editing outcomes. For example, PCR-based methods for deep sequencing can detect the formation of insertions and deletions (indel) after genome editing but cannot quantify gene deletions and do not capture larger structural changes that remove one or both primer sites. Previously, we used 
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Nature MediciNe ddPCR to quantify genetic changes including deletions 4 ; however, ddPCR requires separate priming strategies to amplify each geneediting outcome, including unedited alleles and different editing events, and cannot detect unexpected events. To comprehensively map all possible genome-editing outcomes with an unbiased approach, we adapted Illumina's Nextera-transposon-based library preparation method for unbiased sequencing 30 . This method used a single genome-specific forward primer for target enrichment and a reverse primer specific for the DNA tag integrated by the transposon. In addition to genomic deletions, this method is sensitive to indel formation, inversion of exon 23 and surrounding introns and integration of the AAV genome ( Fig. 3a ). Using this method, we show that quantifiable and heterogenous genome-editing events at the on-target Dmd locus occur, including deletions, inversions, indels, and AAV integrations in all treated mice ( Fig. 3b and Extended Data Fig. 5 ). Importantly, no chromosomal translocations driven by off-target DNA cutting were detected in this experiment (estimated limit of detection of approximately 0.01%; Extended Data Fig. 5 ). The majority of deletion events were perfect deletions consistent with previous observations 4, 31 . We detected a low prevalence (<0.5%) of large asymmetrical deletions ( Fig. 3c and Supplementary Table 3 ), consistent with a previous report using long-read sequencing to monitor genome-editing outcomes in pluripotent cells in vitro 32 . However, our method cannot detect large deletions that remove both primer sites. The sequencing method used here is reproducible and matches indel quantification collected through a more standard next-generation sequencing method (Extended Data Fig. 6 ). We also applied this Nextera-based sequencing approach to cDNA of treated mice. This approach is sensitive to exon 23 removal and unexpected transcript changes including aberrant splicing ( Fig. 3d and Extended Data Fig. 7 ). We detected removal of exon 23, changes in splicing including multi-exon skipping, putative circular RNA formation, and AAV splicing events ( Fig. 3e and Supplementary Tables 4 and 5 ). Splicing events with the AAV vector genome contained canonical splice acceptors or donors (Extended Data Fig. 8 and Supplementary  Table 6 ). Multi-exon skipping may lead to a partially functional or dysfunctional protein, depending on the change to the reading frame. The circular RNAs do not resemble a functional mRNA and will not be translated into protein and therefore are expected to have little biological importance. The relative enrichment of circular RNAs seen here may be caused by the stability of circular RNAs against exonuclease activity 33 . Transcript isoforms that contain partial AAV genomes have an unknown biological effect. The levels of exon 23 excision determined by this sequencing method are comparable to the results obtained by ddPCR analysis for quantification of exon 23 removal (Extended Data Fig. 8 ). Sequencing of the cDNA isolated at different time points indicated that the transcript isoform levels are sustained over 1 year (Extended Data Fig. 7 ).
AAVs are being used extensively as a delivery vector for CRISPRCas9 in preclinical studies to treat inherited diseases including DMD 1, 34 . Although the safety of AAVs as a gene-delivery vehicle has been shown preclinically and through over 100 clinical trials, the potential genotoxicity of the combination of AAV and CRISPR requires further characterization. Here we adapted next-generation sequencing modalities to characterize unintended genome-editing events and AAV genome integrations. In this study, AAV typically integrated within the viral inverted terminal repeats (ITRs, 62%), resembling canonical integration 35 ; however, insertions within the viral genome were also detected (38%) ( Fig. 4a ). Insertions that occur internally within the vector genome may be the result of vector truncations from AAV packaging or from AAV genome insertion during DNA repair. Separately, a primer specific to the AAV vector genome was used in conjunction with the same transposon-specific primer to map genome-wide AAV vector episome integration into the mouse genome ( Fig. 4b ). This showed that the targeted site within the Dmd gene was the preferential location for integration in both neonatal liver and cardiac muscle. In tissues that were analyzed 8 weeks after systemic delivery in neonatal mice, 94 AAV integration sites were identified in the liver and 72 sites in cardiac muscle, with the majority of integration events 
Fig. 2 | Host response to AAV-CRISPR for DMD. a, Antibodies against
SaCas9 are detected in mice treated as adults but not in mice treated as neonates after 8 weeks or 1 year (one-way ANOVA with multiple comparisons *P < 0.05, **P < 0.01 compared with untreated mice at 8 weeks, n numbers as indicated). b, Mice injected as adults with an AAV encoding Cas9 have T cells that are stimulated by exposure to SaCas9 to produce IFNγ as shown by enzyme-linked immune absorbent spot (ELISpot, one-sided t-test, *P = 0.0246, n = 3 mice per condition). SFCs, spot-forming colonies. c,d, A significant loss in total AAV vector genomes (vg) per diploid genome (dg) is detected in skeletal muscle following intramuscular injection and intravenous injection but not in cardiac muscle and diaphragm (two-way ANOVA with Tukey's multiple comparisons test, n = 7, i.m., 8 weeks; n = 5, i.m., 6 months, n = 4, all systemic groups). NS, not significant. e,f, Expression of both the Cas9 mRNA and gRNAs dissipates between the early and late time points. Skeletal muscle also shows lower gRNA expression than cardiac muscle (two-way ANOVA with Tukey's multiple comparisons test, n = 4, all groups). Data are mean ± s.e.m.
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Nature MediciNe occurring within introns of genes consistent with previous observations, including several previously identified integration sites 36 ( Fig. 4c and Supplementary Table 7 ). Several putative gRNA offtarget sites were also identified by AAV integration (Fig. 4b,d ), including a previously predicted off-target site in an intergenic region of chromosome 14 for which there was no detectable activity by conventional targeted deep sequencing in the same samples 4 (Fig. 4c ). This suggests that unbiased mapping of AAV integrations may be a more sensitive approach to determine the specificity of genome-editing reagents than typical methods.
In this study, the frequency of AAV integrations into the CRISPRinduced double-stranded break was higher than the intended deletion ( Fig. 3b ). AAV integration into targeted double-stranded breaks was reported more than a decade ago 35 and has also been applied as a therapeutic gene therapy approach 14 . AAVs can integrate into random breaks across the genome by non-homologous end-joining and can also be copied into target loci by homologous recombination without expression of nucleases 37 . Preclinical reports of hepatocellular carcinoma caused by genotoxicity of the vector have been controversial and risks can be managed by vector design 36,38-40 . AAVs are currently the gene delivery vehicle for more than 100 clinical trials targeting liver, skeletal muscle, cardiac muscle, central nervous system and other tissues with no reported adverse events caused by genotoxicity of the vector. However, the induction of a novel DNA break by any genome-editing construct could potentially change the integration landscape and genotoxicity profile of the AAV (Fig. 4b-d ). Additionally, each genome-engineering construct will have different genome-wide insertional mutagenesis profiles and should be carefully considered when developing vectors for therapeutic genome editing. Preclinical work can monitor cis activation of oncogenes and clonal expansion of AAV integration sites to reduce potential genotoxicity risks of genome-editing technologies delivered by AAVs 36 , analogous to efforts to characterize lentiviral vector integration, which also has an excellent safety profile in human clinical trials.
Important future preclinical developments will be focused on increasing the overall editing efficiency and increasing the proportion of the intended gene modification by optimizing delivery and the gene-editing strategy. This study further establishes the feasibility of permanent gene correction as a therapeutic approach for DMD and potentially other diseases. Despite the presence of a host response to Cas9 and persistent unintended genome modifications, AAV-CRISPR was well-tolerated for 1 year with no sign of toxicity, although much larger studies are required to confirm the absence of genotoxicity risk. Moreover, the restoration of dystrophin expression was sustained over this period. New developments 
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to characterize safety and efficiency in larger animal models and mitigate the potential immune response will be crucial to translate this technology to treat genetic disease.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41591-019-0344-3. Fig. 4 | AAV integrations into the Dmd locus and genome-wide. a, AAV integrations were detected in the gRNA target sites. In total, 62% of integrations occurred within the ITRs and the remaining 38% occurred within the viral genome. AUC, area under the curve; g1, gRNA1; g2, gRNA2; stuffer, promoterless sequence included for AAV packaging. b, A similar approach was used to map AAV integrations genome-wide in both the liver and heart, 8 weeks after systemic administration in neonatal mice. The top hits include the two gRNA target sites flanking exon 23 of the Dmd gene, but numerous other AAV integration sites were detected. c, Genome-wide AAV integration sites were primarily located within the introns of genes. d, Possible sites of CRISPR offtarget activity were identified by searching for sequences similar to the intended gRNA on-target site nearby the recovered genomic AAV integrations. PAM, protospacer adjacement motif. 
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Methods AAV preparation. SaCas9-and gRNA-containing AAV constructs were generated as previously described 4 . In brief, a SaCas9 expression plasmid with a CMV promoter containing ITRs and a plasmid containing two gRNA expression cassettes driven by the human U6 polIII promoter were used to prepare recombinant AAV8 and AAV9. ITRs were confirmed by SmaI digestion before AAV production. Multiple batches of AAV8 and AAV9 were produced and titers measured by qPCR as previously described.
In vivo administration of AAV-CRISPR. All experiments involving animals were conducted with strict adherence to the guidelines for the care and use of laboratory animals of the National Institute of Health (NIH). All experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at Duke University. The mouse strain C57BL/10ScSn-Dmdmdx/J (mdx) was obtained from Jackson laboratories. C57BL/10 mice were used as a wild-type control. Adult 8-week-old male mice were administered locally into the tibialis anterior muscle with 30 µl of 5.6 × 10 11 vector genomes per vector per mouse. Adult 8-week-old mice were administered intravenously with 200-µl injections of 2.7 × 10 12 vector genomes per vector per mouse. Two-day-old (P2) neonatal mice were administered intravenously through the facial vein 41 with 5.4 × 10 11 vector genomes per vector per mouse. At set time points (Fig. 1a) , mice were euthanized and the organs collected for experiments involving multiple skeletal muscles, cardiac muscles, other organs and serum.
Genomic DNA extraction and next-generation sequencing. Genomic DNA was extracted from various mouse tissues at defined time points by digestion in proteinase K and ALT buffer at 56 °C overnight while shaking. DNA was further extracted with the DNeasy kit (Qiagen). Endpoint PCR to confirm deletion was performed with AccuPrime Polymerase (Invitrogen) using primers DMDin22F and DMDin23R (Supplementary Table 8 ). Indel formation was detected by nextgeneration sequencing. Amplicons were produced by PCR using AccuPrime Polymerase (Invtrogen) and a series of primers for each locus (Supplementary Table 8 ). A second short-cycle PCR was used to add Illumina flowcell-binding sequences and experiment-specific barcodes (Supplementary Table 8 ). The resulting PCR products were sequenced with 150-bp paired-end reads on an Miseq instrument (Illumina). Indel analysis was performed using a local distribution of CRISPResso Pooled 42 using a 5-bp window and standard settings.
Transposon-mediated target enrichment and sequencing. Using a Nextera Tn5 transposon (Illumina), 100 ng to 1 μg genomic DNA was tagmented following the manufacturer's instructions, except the transposon was diluted 1:8 from specifications to encourage large fragment size (Extended Data Fig. 9 ). To enrich the targeted sequence, a single PCR reaction using a genome specific primer (DMDin22-Nextera-F or DMDin23-Nextera-R) was used paired with a reverse primer specific for the tag sequence inserted by the transposon (Nextera-R) for 25cycles. Amplicons were purified with Ampure beads (Beckman Coulter) at 1.8×. A short 10-cycle PCR was used to add experimental barcodes and Illumina adapter sequences. Amplicons were gel-purified selecting the fragment size shown in Extended Data Fig. 9 . Sequencing was conducted on an Illumina Miseq using v.2 chemistry and 2 × 150-cycle paired-end reads. Analysis was performed by aligning amplicons to the targeted locus and discarding misprimed sequences. Targeted amplicons ranged from 5 to 40% depending on the primer used (Extended Data Fig. 9 ). Reads were then aligned to the expected products, including deletions, inversions, AAV integrations and genome-wide translocations. Alignments to the AAV genome (Fig. 4a ) used the NeedlemanWunsch algorithm with a GapOpenValue of 10. Some reads within the AAV ITRs were ambiguous and were randomly assigned to one of the two ITRs for alignment. This Nextera-based method is expected to reduce PCR-related bias from amplicon size; however, some bias may remain for the transposon selectivity 30 .
Transcript evaluation and sequencing. RNA was extracted using the Qiagen Universal kit. Subsequently, 1 μg was used to perform First-strand cDNA synthesis using the Vilo kit (ThermoFisher) according to the manufacturer's instructions. cDNA was diluted 1:4 in ultrapure water, aliquoted and stored for further analysis. For transposon-based sequencing, second-strand cDNA synthesis was performed using Klenow fragment DNA polymerase (NEB). cDNA was treated with the Nextera Tn5 transposon at 1:8 the recommended concentration. Enrichment of the target transcript was performed by PCR using transcript-specific primers (Ex22-Nextera-F or Ex24-Nextera-R) and a constant reverse primer specific to the tag inserted by the transposon (Nextera-R). Amplicons were purified by Ampure beads at 1.8× and a second 10-cycle PCR was used to add adapters and barcodes. Reads were aligned to predicted amplicons and mis-aligned reads were discarded. Reads were then aligned to expected products and unexpected products were identified and quantified. qPCR was conducted using QuantaBio PerfeCTa SYBR Green SuperMix using the primers listed in Supplementary Table 8 .
Western blot. Frozen muscle biopsies were disrupted with mortar and pestle and suspended in RIPA buffer (Sigma) with a proteinase inhibitor cocktail (Roche) and incubated for 30 min on ice with intermittent vortexing. Samples were centrifuged at 16,000g for 30 min at 4 °C and the supernatant was isolated and quantified with a bicinchoninic acid assay (Pierce). Protein isolates were mixed with NuPAGE loading buffer (Invitrogen) with 5% β-mercaptoethanol and boiled at 100 °C for 10 min. Samples were flash-frozen in liquid nitrogen and stored at −80 °C. Subsequently, 25 μg of total protein per lane was loaded into a 10 well 4-12% NuPAGE Bis-Tris gel (Invitrogen) with MES buffer (Invitrogen) and electrophoresed for 30 min at 200 V. Proteins were transferred to a nitrocellulase membrane for 1 h at 400 mA at 4 °C in transfer buffer containing 1× Tris-glycine, 10% methanol and 0.01% SDS. The blot was blocked overnight in tris-buffered saline with 0.1% Tween 20 (TBST) with 5% milk at 4 °C. The blot was probed with MANDYS8 (1:200 , Sigma D8168) and rabbit anti-GAPDH (1:5,000, Cell Signaling 2118S). The blot was washed with TBST and probed with mouse or rabbit horseradish peroxidase-conjugated secondary antibodies (Sigma) for 30 min in 5% milk-TBST. Blots were visualized using Western-C ECL substrate (Biorad) on a ChemiDoc chemiluminescent system (Biorad). The full blots are shown in the Source data associated with this paper.
Immunofluorescence staining. Skeletal and cardiac muscles were dissected and embedded in OCT using liquid nitrogen-cooled isopentane and stored at −80 °C. Subsequently, 10 μm sections were cut onto pretreated histological slides using a cryostat (Leica). Slides were washed in PBS and blocked in PBS supplemented with 5% FBS and 5% goat serum with 0.5% Triton X-100. Dystrophin was detected with MANDYS8 (1:200, Sigma D8168) in blocking buffer overnight at 4 °C. Slides were washed 3× with PBS for 10 min and the secondary antibody was applied with DAPI (1:5000) for 30 min at room temperature. Slides were washed and mounted with ProLong Gold Antifade Mountant (Invitrogen) and imaged with an inverted microscope (Leica).
Creatine kinase assay. Serum creatine kinase was measured using a Liquid Creatine Kinase Reagent set (Pointe Scientific) following the manufacturer's instructions. In brief, 5 μl of serum was diluted into 20 μl of sterile PBS and incubated with reagent for 2 min and measured by absorbance every minute for three readings at 37 °C using a nanodrop spectrophotometer set for 340 nm readings. Calculations for total creatine kinase in U l −1 were made according to the manufacturer's instructions and plotted relative to levels in serum samples from wild-type mice.
Recombinant SaCas9 production. A plasmid containing an IPTG-inducible bacterial SaCas9 expression cassette was transformed into Rosetta 2 cells (Millipore EMD) and plated on LB plates with 50 μgml −1 kanamycin and 30 μgml −1 chloramphenicol. Colonies were selected and grown in a starter culture overnight then in a 1 l culture for 4-6 h until the optical density at 600 nm reached 0. Fig. 3b . a, Quantitative data for genome-editing measurements are an average of n = 4 individual mice. Skeletal and cardiac muscle are shown on a separate scale from liver samples. b, Comparison of deep sequencing for both gRNAs. c-g, Comparison of indel rates for gRNA1 to identify alternate modifications. h-l, Comparison of indel rates of gRNA2 with alternate modifications. Rare events have poorer correlations. An estimated limit of detection is given based on the inversions detected that range between 0.1% and 0.2%. The limit of detection could be decreased with more input DNA and increased number of reads to detect more rare events, possibly including translocations. 
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Data collection
Sequencing data was collected by illumina sequencing.
Data analysis
Targeted deep sequencing was analyzed through online software (CRISPResso available from http://github.com/lucapinello/CRISPResso). Further interpretation was made using a custom matlab pipeline. Nextera-based sequencing and AAV integration sequencing used custom matlab code to align all reads the genome and then to a list of the expected products. For genome-wide AAV integration, 3' ends of the reads were aligned to the mm10 genome using BLAT. Matlab-based code can be made available upon request and has been uploaded to https://github.com/chrisnelsonlab/CRISPR-Nextera/.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
